A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Mayo Clinic Cancer Center, Phoenix, Arizona, United States

Arkansas Urology, Little Rock, Arkansas, United States

Loma Linda University, Loma Linda, California, United States

Providence Medical Institute, Santa Monica, California, United States

Clinical Research Center of Florida, Pompano Beach, Florida, United States

John Hopkins University, Baltimore, Maryland, United States

Adult & Pediatric Urology, PC, Omaha, Nebraska, United States

Urology Las Vegas, Las Vegas, Nevada, United States

Manhattan Medical Research, New York, New York, United States

Weill Cornell Medical College, New York, New York, United States

Montefiore Medical Center (Albert Einstein), New York, New York, United States

Western New York Urology Associates, New York, New York, United States

The University of North Carolina, Chapel Hill, North Carolina, United States

Penn State Hershey State College, Hershey, Pennsylvania, United States

Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

Urology Associates, PC, Nashville, Tennessee, United States

Urology San Antonio, Fredericksburg, Texas, United States

Carmel Medical Center, Haifa, Israel

Rabin Medical Center, Petah Tikva, Israel